Annexon Yönetim
Yönetim kriter kontrolleri 4/4
Annexon CEO'su Doug Love, Dec2014 tarihinde atandı, in görev süresi 9.92 yıldır. in toplam yıllık tazminatı $ 2.45M olup, şirket hissesi ve opsiyonları dahil olmak üzere 24.2% maaş ve 75.8% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.28% ine doğrudan sahiptir ve bu hisseler $ 1.53M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.5 yıl ve 6.1 yıldır.
Anahtar bilgiler
Doug Love
İcra Kurulu Başkanı
US$2.5m
Toplam tazminat
CEO maaş yüzdesi | 24.2% |
CEO görev süresi | 9.9yrs |
CEO sahipliği | 0.3% |
Yönetim ortalama görev süresi | 2.5yrs |
Yönetim Kurulu ortalama görev süresi | 6.1yrs |
Son yönetim güncellemeleri
Recent updates
We're Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash Wisely
Sep 27Speculative "Buy" Rating On Annexon: Evaluating The Potential Of ANX005 For GBS
Aug 17Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place
Jun 04Annexon: Unforced Error Sullies Prospects
Apr 03Here's Why We're Watching Annexon's (NASDAQ:ANNX) Cash Burn Situation
Nov 10Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?
Jul 25Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?
Apr 11Are Investors Undervaluing Annexon, Inc. (NASDAQ:ANNX) By 25%?
Feb 14We Think Annexon (NASDAQ:ANNX) Needs To Drive Business Growth Carefully
Dec 28Annexon started as a buy at Jefferies on market potential of candidates, data catalysts
Sep 16Annexon: A First Take
Aug 21Annexon Biosciences GAAP EPS of -$0.96 misses by $0.02
Aug 08Annexon to raise $130M in stock and warrant offering
Jul 08We're Keeping An Eye On Annexon's (NASDAQ:ANNX) Cash Burn Rate
Apr 16Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth
Jan 01Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth
Sep 08We Think Annexon (NASDAQ:ANNX) Can Afford To Drive Business Growth
May 22We Think Annexon (NASDAQ:ANNX) Can Afford To Drive Business Growth
Feb 06Dosing underway in Annexon's Phase 2/3 study of monoclonal antibody in Guillain-Barré Syndrome
Dec 21Annexon Biosciences EPS misses by $0.43
Nov 16CEO Tazminat Analizi
Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
---|---|---|---|
Sep 30 2024 | n/a | n/a | -US$118m |
Jun 30 2024 | n/a | n/a | -US$115m |
Mar 31 2024 | n/a | n/a | -US$121m |
Dec 31 2023 | US$2m | US$593k | -US$134m |
Sep 30 2023 | n/a | n/a | -US$141m |
Jun 30 2023 | n/a | n/a | -US$143m |
Mar 31 2023 | n/a | n/a | -US$145m |
Dec 31 2022 | US$4m | US$569k | -US$142m |
Sep 30 2022 | n/a | n/a | -US$145m |
Jun 30 2022 | n/a | n/a | -US$145m |
Mar 31 2022 | n/a | n/a | -US$140m |
Dec 31 2021 | US$8m | US$534k | -US$130m |
Sep 30 2021 | n/a | n/a | -US$116m |
Jun 30 2021 | n/a | n/a | -US$103m |
Mar 31 2021 | n/a | n/a | -US$84m |
Dec 31 2020 | US$5m | US$446k | -US$70m |
Sep 30 2020 | n/a | n/a | -US$56m |
Jun 30 2020 | n/a | n/a | -US$45m |
Mar 31 2020 | n/a | n/a | -US$42m |
Dec 31 2019 | US$3m | US$396k | -US$38m |
Sep 30 2019 | n/a | n/a | -US$34m |
Jun 30 2019 | n/a | n/a | -US$28m |
Mar 31 2019 | n/a | n/a | -US$23m |
Dec 31 2018 | US$518k | US$379k | -US$18m |
Tazminat ve Piyasa: Doug 'ın toplam tazminatı ($USD 2.45M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 2.14M ).
Tazminat ve Kazançlar: Doug 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Doug Love (56 yo)
9.9yrs
Görev süresi
US$2,453,184
Tazminat
Mr. Douglas Love, Esq., J.D, also known as Doug, has been the President, Director and Chief Executive Officer of Annexon Inc. since December 2014. He has extensive business and legal leadership experience...
Liderlik Ekibi
İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
---|---|---|---|---|
CEO, President & Director | 9.9yrs | US$2.45m | 0.28% $ 1.5m | |
Chief Scientific Officer & Executive VP | 1.8yrs | US$1.83m | 0.047% $ 258.7k | |
Executive VP | 3.1yrs | US$1.14m | 0.067% $ 366.8k | |
Executive VP | 5.4yrs | US$1.44m | 0.026% $ 141.5k | |
Executive VP & Chief Business Officer | 4.3yrs | US$1.40m | 0.033% $ 183.4k | |
Senior Vice President of Translational Medicine | no data | Veri yok | Veri yok | |
Executive VP & Chief Medical Officer | 1.3yrs | Veri yok | Veri yok | |
Senior VP & Head of Commercial | less than a year | Veri yok | Veri yok | |
Senior VP of Medical Affairs | less than a year | Veri yok | Veri yok |
2.5yrs
Ortalama Görev Süresi
59.5yo
Ortalama Yaş
Deneyimli Yönetim: ANNX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.5 yıldır).
Yönetim Kurulu Üyeleri
İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
---|---|---|---|---|
CEO, President & Director | 9.9yrs | US$2.45m | 0.28% $ 1.5m | |
Executive VP | less than a year | US$1.14m | 0.067% $ 366.8k | |
Independent Director | 9.9yrs | US$103.93k | 0.76% $ 4.1m | |
Independent Chairman | 7.8yrs | US$132.43k | 0.00025% $ 1.4k | |
Independent Director | 4.4yrs | US$100.93k | 0% $ 0 | |
Independent Director | 3.3yrs | US$103.43k | 0% $ 0 | |
Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
Member of Scientific Advisory Board | no data | Veri yok | Veri yok |
6.1yrs
Ortalama Görev Süresi
66yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: ANNX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.1 yıldır).